Pfizer nears deal to acquire angiosyn, Pad eye drug roster
Pfizer Inc.is close to an agreement to buy Angiosyn Inc., a La Jolla, California, biotech start-up working on a drug to ward off blindness, in a deal potentially valued at $527 million, according to